Liquid Biopsy CDx Test for Advanced Non-small Cell Lung Cancer Receives FDA Approval

The US Food and Drug Administration (FDA) has approved Agilent Resolution ctDx FIRST as a companion diagnostic (CDx) to identify advanced non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations who may benefit from treatment with KRAZATITM (adagrasib). Click to read more...

Related Keywords

Alan Sandler ,Kenna Anderes ,Sam Raha ,Genomics Group ,Drug Administration ,Agilent Resolution ,Vice President ,Translational Medicine ,Chief Medical ,Ctdx ,Patients ,Approved ,Agilent ,Dvanced ,Dancer ,Nsclc ,Profiling ,Enomic ,Iagnostics ,